Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

Ipsen withdrew tazemetostat worldwide for follicular lymphoma and epithelioid sarcoma after new trial data suggested a less favorable safety profile than previously characterized. SYMPHONY-1 ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all ...

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...

The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is ...

“[I thought] I had an intolerance to vodka," said Claire Dougherty ...

A $7.25 billion class action settlement meant to resolve claims that Monsanto’s Roundup products caused cancer in people has ...